Striant Articles
1994 Brings Israel's BTG Closer To Goals
3 July 1995
Benefits Of Drug Delivery Systems For Generics
5 June 1995
Trimpatch approved in Mexico
29 May 1995
Nichiiko has license to produce estrogen
29 May 1995
Pharma Resources Ups Stake In Sano
29 May 1995
Rhone-Poulenc Rorer has UK approval for Menorest
22 May 1995
Grelan To Distribute TheraTech Patch
24 April 1995
Alza Wins Motion To Dismiss Cygnus Case
24 April 1995
CSM Clamps Down On Cyproterone Acetate..
27 March 1995
L10 Million Interim Funding For Shire Pharma
6 March 1995
Successful POM To OTC Switching In The UK
27 February 1995
Metra Biosystems; Focus On Bone Disorders
20 February 1995
R-PR Looks To New Products For Growth
20 February 1995
Search For Growth Drivers At Rhone-Poulenc Rorer
13 February 1995
Alza And Marion Merrell Dow Files Suit
6 February 1995
Janssen-Cilag's Durogesic Patch Launched In UK
30 January 1995
Shire And Sekisui Sign Joint Agreement
23 January 1995
R-PR's Menorest Approved In France
16 January 1995
Aradigm Looking To Expand Via Agreements
2 January 1995
Ethical Holdings Receives UK Approval
19 December 1994
The Costs Of "Bio-Piracy" To The Third World
19 December 1994
Risperidone For Tourette's
12 December 1994
SB Expands Rights To Testosterone Patch
5 December 1994
1st Approval For R-PR, Noven's Menorest
14 November 1994
Ciba-Geigy's Nicotine Patch Patent Invalid
17 October 1994
Schein/Ethical Holdings Agreement
12 September 1994
Male Contraceptive
5 September 1994
ROBERTS COMPLETES APPLICATION FROM SEARLE
11 July 1994
hGH IN JAPAN BOOSTS BIOTECH GENERAL SALES
13 June 1994
ALZA PRODUCT LAUNCH
30 May 1994
GIST-BROCADES BIDS FOR PIERREL UNIT
23 May 1994
UNCERTAINTY OVER SWEDISH OTC PLANS
9 May 1994
CONTRACEPTIVE INJ FOR MEN BY 1996
2 May 1994
PHARMOS: AN EYE FOR A PRODUCT TARGET
2 May 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
TRANSDERMAL INSULIN BREAKTHROUGH
11 April 1994
NOVEN RECEIVES APPROVABLE LETTER
11 April 1994
ACTISITE CLEARED FOR MARKET IN USA
11 April 1994
OPPORTUNITIES FROM DRUG DELIVERY SYSTEMS
21 February 1994
ALZA IN LAWSUIT
31 January 1994
WORLD PRODUCT NEWS IN BRIEF
24 January 1994
UPJOHN TERMINATES LICENSE AGREEMENT
6 December 1993
FOURNIER MAKES MOVE ON INTERNATIONAL STAGE
6 December 1993
FURTHER RESULTS FROM THE GISSI-3 STUDY
15 November 1993
FIRST RESULTS FROM GISSI-3 STUDY
8 November 1993
ALZA'S TESTODERM
8 November 1993
ALZA'S MALE HORMONE PATCH APPROVED
25 October 1993
FUJISAWA FILES NDA FOR PROGRAF
13 September 1993
TESTOSTERONE GEL AND HEART DISEASE
23 August 1993
CYGNUS TO FILE FOR ALPRAZOLAM PATCH
23 August 1993
US OB-GYN DRUG MARKET TO DOUBLE
23 August 1993
NICOTINE PATCH COs SUFFER DECLINE IN US SALES
2 August 1993
MANOPLAX DEFEATED BUT BOOTS SHARES RALLY
26 July 1993
INVESTMENT PROSPECTS IN UK BIOSCIENCE GROUPS
28 June 1993
ANABOLIC STEROIDS FOR AIDS WASTING?
21 June 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
ISRAEL'S GYNEX AND USA'S BTG TO MERGE
21 June 1993
REPORT SLAMS US LABELING ABROAD
31 May 1993
ADAPTING TO HEALTH CARE REFORM THE SB WAY
17 May 1993
NEW INDICATION FOR LUPRON DEPOT-PED
10 May 1993
ADVANCES AND SLOW DOWNS IN US 1st QTRS
3 May 1993
CIBA'S 1st QTR 1993 SALES DOWN 4%
26 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
CIBA'S 1st QTR COULD BE SLOWER THAN 1992 1st QTR
12 April 1993
SMITHKLINE BEECHAM LICENSES THREE DRUGS
5 April 1993
BIOT-TECHNOLOGY GENERAL TO ACQUIRE GYNEX
22 March 1993
THERATECH FILES NDA
1 March 1993
EVOREL LAUNCH
22 February 1993
JOUVEINAL PRODUCTS EFFECT ON W-L PIPELINE
8 February 1993
RHONE-POULENC RORER SALES $4 BILLION IN 1992
8 February 1993
MYLAN ACQUIRES BERTEK
4 January 1993
NEW ATHEROSCLEROSIS GUIDELINES FOR EUROPE
14 December 1992
SEKISUI LAUNCHES ISDN PREPARATION
14 December 1992
ALZA is STILL A STRONG BUY
14 December 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
US RESULTS 3RD QTR
2 November 1992
TABAZUR LAUNCHED IN FRANCE
12 October 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
CARDIZEM CD FOR ANGINA
12 October 1992
GYNEX' SUBLINGUAL TESTOSTERONE
5 October 1992
RHONE-POULENC RORER REVIEWS DRUG PRIORITIES
5 October 1992
MMD'S NICODERM IN FULL SUPPLY
5 October 1992
ELAN CORP FUTURE LOOKS BETTER THAN EXPECTED
3 August 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
R-PR AND NOVEN SIGN HRT AGREEMENT
6 July 1992
Alza et al in out-of-court settlement
8 June 1992
MERCK'S PROSCAR GETS 2nd APPROVAL
8 June 1992
1st NICOTINE PATCH LAUNCHED IN UK
8 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
Male Menopause ?
8 June 1992
GYNEX PRODUCT AIDS TURNER'S PATIENTS
8 June 1992
NICOTINE PATCH SHORTAGE IN USA
1 June 1992
WIDESPREAD IGNORANCE ABOUT HRT IN UK
18 May 1992
EUROPEAN MARKET FOR SELF-MEDICATION
18 May 1992
3rd QTR LAUNCH IN USA FOR NICOTROL
11 May 1992
GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN
4 May 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
